As far as revenue goes, you may be missing any attribution to growth in 2HFY23.
Sure, 1HFY23 revenue was A$10.44 for about 110,000 cycles so that's an achieved price of $95/cycle.
For 2HFY23 the CEO has already stated that cycles in December 2022 were 20,000 and by February cycles were growing by 5%/week, so if one was to assume those figures for the remainder of the year, that's about 240,000 cycles for the second half and possibly A$20-25M for 2HFY23.
So my figures for FY23 are closer to A$35 than $20.
My projection on this basis, is that we will be exiting June with a weekly sales cycle of between 14,000 to 20,000 and if no further growth occurred in FY2024 we will have sales of between A$70 and A$100 m for FY 24. That's a profitable product, sure not the US$200M projected. With modest 2% weekly growth in FY2024 we are looking at closer to A$140M.
- Forums
- ASX - By Stock
- Ann: Change in substantial holding
MYX
mayne pharma group limited
Add to My Watchlist
3.27%
!
$5.03

As far as revenue goes, you may be missing any attribution to...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.03 |
Change
-0.170(3.27%) |
Mkt cap ! $408.6M |
Open | High | Low | Value | Volume |
$5.20 | $5.21 | $5.03 | $2.804M | 555.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 14654 | $5.03 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.14 | 3111 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 5.010 |
2 | 61000 | 5.000 |
2 | 2200 | 4.990 |
2 | 702 | 4.970 |
3 | 2200 | 4.950 |
Price($) | Vol. | No. |
---|---|---|
5.140 | 3111 | 2 |
5.150 | 19052 | 1 |
5.180 | 396 | 1 |
5.200 | 2000 | 1 |
5.300 | 10000 | 1 |
Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |